Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial.

Kumar, Ajay; Franek, Edward; Wise, Jonathan; Niemeyer, Marcus; Mersebach, Henriette; Simó, Rafael

Kumar, Ajay; Franek, Edward; Wise, Jonathan; Niemeyer, Marcus; Mersebach, Henriette; Simó, Rafael.

Affiliation

Kumar A; Diabetes Care & Research Centre, Near Overbridge, Kankarbagh, Patna, Bihar, India.
Franek E; Medical Research Center, Polish Academy of Sciences and Central Clinical Hospital MSWiA, Warsaw, Poland.
Wise J; Tulane Medical School, Department of Endocrinology, New Orleans, LA, United States of America.
Niemeyer M; Market Access and Public Affairs, Novo Nordisk Pharma GmbH, Mainz, Germany.
Mersebach H; Clinical Development & Research-Diabetes & Obesity, Novo Nordisk Inc, Princeton, NJ, United States of America.
Simó R; Diabetes and Metabolism Research Unit, Autonomous University of Barcelona, Vall d'Hebron Institute de Recerca, and CIBERDEM, Barcelona, Spain.

PLoS One ; 11(10): e0163350, 2016.

Article in En | MEDLINE | ID: mdl-27760129

Subject(s)

Diabetes Mellitus, Type 2/drug therapy; Insulin Glargine/adverse effects; Insulin Glargine/therapeutic use; Insulin, Long-Acting/adverse effects; Insulin, Long-Acting/therapeutic use; Safety; Blood Glucose/metabolism; Body Weight/drug effects; Diabetes Mellitus, Type 2/blood; Drug Combinations; Female; Humans; Male; Middle Aged

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Safety / Insulin, Long-Acting / Diabetes Mellitus, Type 2 / Insulin Glargine Type of study: Clinical_trials Limits: Female / Humans / Male / Middle aged Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2016 Document type: Article Affiliation country: India Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google